The European Union has announced that the ThermoBreast proposal has been successfully evaluated and that they will be investing 12.12 million euros into the project, an innovative and non-contact breast cancer detection and patient monitoring system. This project, coordinated by ThermoMind LTD, is set to revolutionise the way breast cancer is detected, with a risk-free screening technology that can detect vascular anomalies and asymmetry caused by cancerous growth. ThermoBreast is a multidisciplinary consortium of 16 partners from 10 countries, and aims to reduce the burden of breast cancer on women, healthcare professionals, and their families. The project combines advanced ICT and life sciences technologies to create a medical class 1 device that will be validated in an international multicentre clinical study. The European Union’s investment in the ThermoBreast project is a step towards their mission on cancer and beating cancer plan, and is expected to greatly improve the prevention, diagnosis, and monitoring of breast cancer.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them (grant agreement no. 101096329).
Swiss participants in this project are supported by the Swiss State Secretariat for Education, Research and Innovation (contract no. 22.00518).
